MAMaher Albitar

Maher Albitar

*This is an algorithmically generated author record based on publicly available information.

Maher Albitar has a total of 123 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Circulating Ki-67 index in plasma as a biomarker and prognostic indicator in chronic lymphocytic leukemia

    by Jean-Marie Bruey, Hagop Kantarjian, Wanlong Ma, Zeev Estrov, Chenhsiung Yeh, Amber Donahue, Heather Sanders, Susan O’brien, Michael Keating, Maher Albitar


  • Open Access

    JAK2 Exon 14 Deletion in Patients with Chronic Myeloproliferative Neoplasms

    by Wanlong Ma, Hagop Kantarjian, Xi Zhang, Xiuqiang Wang, Zhong Zhang, Chen-Hsiung Yeh, Susan O'Brien, Francis Giles, Jean Marie Bruey, Maher Albitar

    The JAK2 V617F mutation in exon 14 is the most common mutation in chronic myeloproliferative neoplasms (MPNs); deletion of the entire exon 14 is rarely detected. In our previous study of >10,000 samples from patients with suspected MPNs tested for JAK2 mutations by reverse transcription-PCR (RT-PCR) with direct sequencing, complete deletion of exon 14 (Δexon14) constituted JAK2 mutations. This appears to be an alternative splicing mutation, not detectable with DNA-based testing. We investigated the possibility that MPN patients may express the JAK2 Δexon14 at low levels (JAK2 Δexon14 mRNA expression relative to wild-type, we tested 61 patients with confirmed MPNs, 183 with suspected MPNs (93 V617F-positive, 90 V617F-negative), and 46 healthy control subjects. The Δexon14 variant was detected in 9 of the 61 (15%) confirmed MPN patients, accounting for 3.96% to 33.85% (mean = 12.04%) of total JAK2 transcript. This variant was also detected in 51 of the 183 patients with suspected MPNs (27%), including 20 of the 93 (22%) with V617F (mean [range] expression = 5.41% [2.13%–26.22%]) and 31 of the 90 (34%) without V617F (mean [range] expression = 3.88% [2.08%–12.22%]). Immunoprecipitation studies demonstrated that patients expressing Δexon14 mRNA expressed a corresponding truncated JAK2 protein. The Δexon14 variant was not detected in the 46 control subjects. These data suggest that expression of the JAK2 Δexon14 splice variant, leading to a truncated JAK2 protein, is common in patients with MPNs. This alternatively spliced transcript appears to be more frequent in MPN patients without V617F mutation, in whom it might contribute to leukemogenesis. This mutation is missed if DNA rather than RNA is used for testing.


  • Clinical correlation of circulating heat shock protein 70 in acute leukemia

    by Chen-Hsiung Yeh, Richard Tseng, Alison Hannah, Zeev Estrov, Elihu Estey, Hagop Kantarjian, Maher Albitar


  • Plasma levels of JAK2 mRNA in patients with chronic myeloproliferative diseases with and without V617F mutation: implications for prognosis and disease biology

    by W. Ma, H. Kantarjian, X. Zhang, C.‐H. Yeh, Z. J. Zhang, S. Verstovsek, S. O’bRien, F. Giles, M. Albitar

    Summary: The association of V617F JAK2 expression levels with disease behavior has not been studied in patients with nonchronic myelogenous leukemia (CML) myeloproliferative disease (MPD). We found plasma levels of total JAK2 mRNA to be higher in patients with non‐CML MPD (n = 175) than in CML patients (n = 45) and normal controls (n = 58) (each P < 0.001). Overall survival was studied in 68 patients and showed positive correlation with levels of total and mutant JAK2 mRNA in patients with the V617F mutation, but not those without the mutation. These findings suggest that total JAK2 expression levels play a role in the biology of the disease in V617F‐positive patients, and a therapy aiming at downmodulating the expression of the total JAK2 mRNA should be considered. In conclusion, we studied JAK2 total and V6217F mutant mRNA levels in plasma. We show high levels of JAK2 expression in MPD patients and these levels correlate with survival.


  • Antibodies in Biosensing

    by Amber C. Donahue, Maher Albitar


  • Proteomics-based prediction of clinical response in acute myeloid leukemia

    by Maher Albitar, Steven J. Potts, Francis J. Giles, Susan O'BRien, Iman Jilani, Amber C. Donahue, Elihu H. Estey, Hagop Kantarjian


  • Proteasome Enzymatic Activities in Plasma as Risk Stratification of Patients with Acute Myeloid Leukemia and Advanced-Stage Myelodysplastic Syndrome

    by Wanlong Ma, Hagop Kantarjian, Benjamin Bekele, Amber C. Donahue, Xi Zhang, Zhong J. Zhang, Susan O'BRien, Elihu Estey, Zeev Estrov, Jorge Cortes, et al.

    Purpose: Cytogenetic abnormalities are currently the most important predictors of response and clinical outcome for patients with acute myeloid leukemia (AML) or advanced-stage myelodysplastic syndrome (MDS). Because clinical outcomes vary markedly within cytogenetic subgroups, additional biological markers are needed for risk stratification. Experimental Design: We assessed the utility of measuring pretreatment proteasome chymotrypsin-like, caspase-like, and trypsin-like activities in plasma to predict response and survival of patients with AML (n = 174) or advanced-stage MDS (n = 52). Results: All three enzymatic activities were significantly (P < 0.001) increased in the plasma of patients with AML and MDS compared with normal controls. Both chymotrypsin-like and caspase-like activities, but not trypsin-like activity, correlated with outcome. Chymotrypsin-like and caspase-like activities, but not trypsin-like activity, predicted response in univariate analysis (P = 0.002). However, only chymotrypsin-like activity was independent predictor of response from age grouping (P < 0.0001), but only chymotrypsin-like activity was independent of cytogenetics, age, performance status, blood urea nitrogen, and β2-microglobulin in multivariate Cox regression models. Chymotrypsin-like activity was also a strong independent predictor of survival in patients with intermediate karyotype (n = 124). Conclusions: Measuring plasma chymotrypsin-like activity may provide a powerful biomarker for risk stratification in patients with AML and advanced-stage MDS, including those with normal karyotype.


  • Plasma-based detection of clonality in lymphoid malignancies

    by Chen-Hsiung Yeh, Richard Tseng, Maher Albitar

    Plasma has been found to be enriched with tumor-specific DNA, RNA, and protein in patients with hematologic disease. We assessed the utility of plasma as a DNA source for detection of genetic abnormalities in patients with suspected B- or T-cell lymphoproliferative disorders. DNA was extracted from paired peripheral blood (PB) cells and plasma for polymerase chain reaction (PCR)-based detection of immunoglobulin heavy chain (IgH) and T-cell receptor gamma chain (TCR-gamma) rearrangements, and B-cell leukemia/lymphoma (BCL)-1/IgH and BCL-2/IgH translocations. Concordance between plasma and PB cell analysis was 100% for IgH (n = 57), TCR-gamma (n = 57), and BCL-1/IgH (n = 37) rearrangements, and 94% (60/64) for BCL-2/IgH; four of 11 plasma samples positive for BCL-2/IgH tested negative in paired cells. No plasma or PB cell samples from 195 healthy donors showed genetic abnormalities. These findings indicate that plasma is a reliable sample type for detection of abnormalities associated with B- and T-cell lymphoproliferative disorders, providing sensitivity equal to or greater than that of PB cells.


  • Open Access

    BCR-ABL Truncation due to Premature Translation Termination as a Mechanism of Resistance to Kinase Inhibitors

    by Wanlong Ma, Hagop Kantarjian, Chen-Hsiung Yeh, Zhong J. Zhang, Jorge Cortes, Maher Albitar

    The Philadelphia (Ph) chromosome, a shortened version of chromosome 22, results from a reciprocal translocation between chromosomes 9q34 and 22q11 [1,2,3]. The Ph translocation positions the c-ABL gene of chromosome 9 downstream from the breakpoint cluster region (BCR) on chromosome 22; the resulting fusion gene produces a 190- or 210-kDa hybrid protein with constitutive kinase activity associated with chronic myelogenous leukemia (CML). The impressive clinical efficacy of imatinib mesylate, a selective and effective ABL kinase inhibitor, has revolutionized the treatment of CML. However, the development of resistance to imatinib, which occurs over months to years, constitutes a major drawback in the treatment of advanced CML [4, 5]. Mechanisms leading to drug resistance include amplification of the BCR-ABL gene, acquired additional genomic alterations, and most importantly, specific mutations within the ABL kinase domain that impede drug binding [2, 3,6,7,8].


  • Circulating heat shock protein 70 and progression in patients with chronic myeloid leukemia

    by Chen-Hsiung Yeh, Richard Tseng, Zhong Zhang, Jorge Cortes, Susan O’brien, Francis Giles, Alison Hannah, Zeev Estrov, Michael Keating, Hagop Kantarjian, et al.